Hypopigmentation Disorders Treatment Market by Treatment Type (Topical Drugs, Chemical Peels, Laser Therapy, and Microdermabrasion), Disease Indication (Albinism, and Vitiligo), End User (Dermatology Centers, Aesthetic Clinics, and Hospitals) - Analysis & Forecast 2019-2030
Report ID : 38 | Published Date : Mar 2019 | Pages : 150 | Region : Global | Report Code : MD-21
Hypopigmentation Disorders Treatment Market Overview and Introduction
The global hypopigmentation disorder treatment market is anticipated to reach a CAGR over 5.5% during the forecast period. Hypopigmentation is a skin condition, where the skin looses the color or skin pigments due to decrease in melanin or melanocyte. The formation of pigmented skins may occur in patches or all over the body. Although, hypopigmentation may occur among people of all races, but the occurrence of such a condition is more noticeable among individuals with dark complexion.
The global hypopigmentation disorders treatment market is driven by technological advancements in the pigmentation treatment and therapy arena, increasing patient awareness and health care expenditure, and rising geriatric population. Rising adoption of minimally invasive treatment procedure, increasing medical tourism for aesthetics has been crucial in contributing to increasing growth of the hypopigmentation disorders treatment market. Similarly, increasing incidences of disorders related to hypopigmentation, namely albinism, and vitiligo, is anticipated to further contribute to the rising demand of global hypopigmentation disorder treatment market. However, high cost, complications & risk associated with medical aesthetics products and treatment is likely to restrain the market to a certain extent.
Hypopigmentation Disorders Treatment Market by Treatment Type
On the basis of treatment type, the hypopigmentation disorders treatment market is segmented into topical drugs, chemical peels, laser therapy, microdermabrasion and other treatments. The segment of topical drugs is anticipated to account for the largest share in the hypopigmentation disorders treatments market, owing to wide scale prescription of topical treatment options by dermatologists worldwide.
Hypopigmentation Disorders Treatment Market by Disease Indication
The segment of disease indication can be segmented into albinism, vitiligo indications and other disease indications. Vitiligo segment is constituted a substantial share in 2018, owing to rising incidences of vitiligo and increasing patient population undergoing treatment of the same.
Hypopigmentation Disorders Treatment Market by End Users
Finally, on the basis of end user, the hypopigmentation disorders treatments market is segmented into dermatology centers, aesthetic clinics, and hospitals, and other end user.
Hypopigmentation Disorders Treatment Market by Regions
The global hypopigmentation disorders treatment market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the hypopigmentation disorders treatment market, followed by Europe and Asia Pacific. Asia Pacific will continue to dominate the global hypopigmentation disorders treatments market in the forecast period owing to factors such as growing adoption of minimally-invasive procedures, rising consciousness regarding ones looks, high healthcare expenditures and highly developed healthcare system. However, Asia Pacific is expected to witness the highest CAGR, with the growth in this market centered at China, India, and Japan. Factors such as the rising focus of major players in emerging Asian countries, penetration and adoption of latest technologies, increasing disposable incomes and growing government support are driving the growth of the hypopigmentation disorders treatments market in this region.
Hypopigmentation Disorders Treatment Market Prominent Players
The prominent players in the global hypopigmentation disorders treatments market are ALLERGAN, SkinCeuticals International, PIERRE FABRE GROUP, Episciences, Inc., RXi Pharmaceuticals, Obagi Cosmeceuticals LLC., and Alvogen among others